News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Nov 7, 2019

Summary Toggle aTyr Pharma to Announce Third Quarter Results on November 14th

Management to host conference call and webcast at 5:00 pm EST / 2:00 pm PST SAN DIEGO , Nov. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today
Oct 22, 2019

Summary Toggle aTyr Pharma Announces Research Collaboration with Boston Children’s Hospital

Collaboration to examine the therapeutic efficacy of anti-neuropilin-2 (NRP2) antibodies in potential new roles and indications SAN DIEGO , Oct. 22, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines
Sep 18, 2019

Summary Toggle aTyr Pharma to Participate in September Conferences

SAN DIEGO , Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will be participating in two investor conferences in
Sep 4, 2019

Summary Toggle aTyr Pharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

SAN DIEGO , Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive
Aug 14, 2019

Summary Toggle aTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update

aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients in Q4 2019 Company to host conference call and webcast today, August 14 , at 5:00pm EDT SAN DIEGO , Aug. 14, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
Aug 7, 2019

Summary Toggle aTyr Pharma to Announce Second Quarter 2019 Results on August 14th

Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO , Aug. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it
Aug 6, 2019

Summary Toggle Leading Immunobiology Researcher Dr. David Briscoe Joins aTyr Pharma as Scientific Advisor

Dr. Briscoe to advise company on ongoing development of therapeutics based on the Neuropilin-2 (NRP2) co-receptor and related signaling pathways SAN DIEGO , Aug. 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of
Jul 10, 2019

Summary Toggle aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape

Conference Call Scheduled for Thursday, July 18th @ 2pm Eastern/11am Pacific SAN DIEGO , July 10, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced
Jul 1, 2019

Summary Toggle aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members

SAN DIEGO , July 01, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointments of Jane Gross , Ph.D. and Svetlana Lucas , Ph.D.
Jun 28, 2019

Summary Toggle aTyr Pharma Announces Reverse Stock Split to Regain NASDAQ Compliance

SAN DIEGO , June 28, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its Board of Directors has approved a one-for-14 reverse stock split of